Gilead Sciences’ investigational therapy magrolimab was well-tolerated and effective in untreated acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy, according to data from a Phase 1b trial. These results were presented recently in an oral presentation, titled “The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results,” at the 62nd American Society of Hematology Annual Meeting and Exposition. “In this ongoing study, treatment with magrolimab and…

You must be logged in to read/download the full post.